Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma

NCT00509431 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: Erlotinib + Sirolimus

Sponsor

Jonsson Comprehensive Cancer Center